Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
JRAB CRISPR/Cas9 KO Plasmid (h): sc-410130
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- JRAB CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the JRAB genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: JRAB Antibody (F-5): sc-376675
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
JRAB CRISPR/Cas9 KO Plasmid (h) | sc-410130 | 20 µg | $397.00 |
Overview
MICALL2 encodes JRAB (also known as MICAL-L2), a Rab13 effector that functions as a scaffold linking vesicle trafficking machinery to actin cytoskeleton remodeling at cell–cell junctions. JRAB participates in regulation of adherens and tight junction organization, membrane recycling, and polarized transport, influencing epithelial barrier integrity and directional migration. Through interactions with Rab GTPases and junctional components, MICALL2 contributes to pathways governing cytoskeletal dynamics and intracellular transport. Altered expression or regulation of MICALL2 has been reported in studies of tumor cell invasion and metastasis-related phenotypes, making it relevant for investigating mechanisms of cell polarity loss and motility.
JRAB CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MICALL2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MICALL2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MICALL2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish JRAB protein expression.
This CRISPR knockout system enables efficient generation of MICALL2-deficient cell models for investigation of JRAB signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MICALL2 exon(s) critical for JRAB function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MICALL2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by JRAB CRISPR/Cas9 KO Plasmid (h) and JRAB CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MICALL2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by JRAB HDR Plasmid (h) and JRAB HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MICALL2 homology arms to support homology-directed repair at defined MICALL2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.